- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03124875
PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
October 22, 2021 updated by: LimFlow, Inc.
Pilot Study to Investigate Safety, Effectiveness and Feasibility of LimFlow Stent Graft System for Creating an AV Fistula for the Treatment of Critical Limb Ischemia
This pilot study will investigate the safety, effectiveness and feasibility of the LimFlow Stent Graft System for creating an AV fistula in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive approach for the treatment of Critical Limb Ischemia (CLI) in subjects ineligible for conventional endovascular or surgical limb salvage procedures.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- MedStar Washington Hospital Center
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96817
- Kaiser Permanente
-
-
Michigan
-
Wyoming, Michigan, United States, 49519
- Metro Health, University of Michigan
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- New Mexico Heart Institute
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Health System
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Palmetto Health
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
21 years to 95 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of critical limb ischemia with hemodynamic evidence of severely diminished arterial inflow of the index limb and Rutherford Classification 5 r 6
- Reviewed and approved for eligibility by the Investigator and the Independent Safety Committee (ISC)
Exclusion Criteria:
- Concomitant hepatic or renal insufficiency, thrombophlebitis, deep venous thrombus, coagulation disorder
- Severe heart failure, recent MI or stroke
- Significant peripheral edema or infection that may preclude insertion of a prosthesis or significantly impair wound healing
- Known allergies or contraindications to anti platelet therapy or device materials
- Immunodeficiency disorder or immunosuppressant therapy
- Life expectancy < 12 months
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment
Treated with the LimFlow Stent Graft System
|
Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amputation-free survival
Time Frame: 30 days post-procedure
|
Percentage of subjects with freedom from above-ankle amputation of the index limb and freedom from all-cause mortality
|
30 days post-procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amputation-free survival
Time Frame: 6 months post-procedure
|
Percentage of subjects with freedom from above-ankle amputation of the index limb and freedom from all-cause mortality
|
6 months post-procedure
|
Primary Patency
Time Frame: 30 days post-procedure
|
Percentage of patients with absence of total occlusion of the stent graft without prior clinically-driven major re-intervention of the stent graft.
Total occlusion is defined as absence of flow on color doppler or angiogram and clinically-driven major re-intervention is defined as creation of a new surgical bypass, use of thrombectomy or thrombolysis, or major surgical revision performed for occlusion of the stent graft.
|
30 days post-procedure
|
Primary Patency
Time Frame: 6 months post-procedure
|
Percentage of patients with absence of total occlusion of the stent graft without prior clinically-driven major re-intervention of the stent graft.Total occlusion is defined as absence of flow on color doppler or angiogram and clinically-driven major re-intervention is defined as creation of a new surgical bypass, use of thrombectomy or thrombolysis, or major surgical revision performed for occlusion of the stent graft.
|
6 months post-procedure
|
Secondary Patency
Time Frame: 6 months post-procedure
|
Percentage of patients with absence of total occlusion of the stent graft with or without prior clinically-driven major re-intervention of the stent graft.Total occlusion is defined as absence of flow on color doppler or angiogram and clinically-driven major re-intervention is defined as creation of a new surgical bypass, use of thrombectomy or thrombolysis, or major surgical revision performed for occlusion of the stent graft.
|
6 months post-procedure
|
Limb Salvage
Time Frame: 3, 6, 9, and 12 months post-procedure
|
Percentage of subjects with freedom from above-ankle amputation of the index limb
|
3, 6, 9, and 12 months post-procedure
|
Wound Healing
Time Frame: 3, 6, 9, and 12 months post-procedure
|
Percentage of subjects with completed index wound healing
|
3, 6, 9, and 12 months post-procedure
|
Deterioration in Renal Function
Time Frame: 6 months post-procedure
|
Percentage of subjects with a 25% increase in serum creatinine after using iodine contrast agents, without another clear cause for kidney injury.
|
6 months post-procedure
|
Technical Success
Time Frame: Post-procedure
|
Percentage of subjects with completion of the endovascular procedure and immediate morphological success with successful placement of the arterial and venous catheters in the desired location in the limb, and ability to place the stent graft.
|
Post-procedure
|
Procedural Success
Time Frame: 30 days post-procedure
|
Percentage of subjects with a combination of Technical Success and absence of all-cause mortality, above-ankle amputation or clinically driven major re-intervention of the stent graft.
|
30 days post-procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jihad Mustapha, MD, Metro Health, University of Michigan
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 8, 2017
Primary Completion (ACTUAL)
August 8, 2019
Study Completion (ACTUAL)
January 5, 2021
Study Registration Dates
First Submitted
April 14, 2017
First Submitted That Met QC Criteria
April 18, 2017
First Posted (ACTUAL)
April 24, 2017
Study Record Updates
Last Update Posted (ACTUAL)
October 27, 2021
Last Update Submitted That Met QC Criteria
October 22, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ECO-02527-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Critical Limb Ischemia
-
R3 Vascular Inc.RecruitingCritical Limb Ischemia | Critical Lower Limb Ischemia | Critical Limb-Threatening IschemiaAustralia
-
Fudan UniversityActive, not recruiting
-
University Health Network, TorontoUnknown
-
Changi General HospitalCompletedCritical Limb IschemiaSingapore
-
AnGes USA, Inc.TerminatedCritical Limb IschemiaUnited States, France, Belgium, Canada, Poland, Finland, Denmark, Netherlands, Hungary, Italy, Sweden
-
R-BioPusan National University HospitalCompletedCritical Limb IschemiaKorea, Republic of
-
Pharmicell Co., Ltd.Withdrawn
-
Lifecells, LLC.CompletedCritical Limb IschemiaUnited States
-
Neuromed IRCCSUnknown
Clinical Trials on LimFlow Stent Graft System
-
LimFlow, Inc.RecruitingPeripheral Arterial Disease | Critical Limb Ischemia | Chronic Limb-Threatening IschemiaUnited States
-
EndologixPQ Bypass, Inc.; SyntactxActive, not recruiting
-
Lifetech Scientific (Shenzhen) Co., Ltd.RecruitingAbdominal Aortic AneurysmTurkey, Bulgaria, Greece
-
Terumo CVSVascutek Ltd.CompletedInfrarenal Abdominal Aortic AneurysmCanada, United States
-
NYU Langone HealthCompletedThoracoabdominal Aortic AneurysmsUnited States
-
Bolton MedicalActive, not recruitingAortic Dissection Type BUnited States
-
Medtronic CardiovascularCompletedThoracic Aortic AneurysmUnited States
-
Xijing HospitalChanghai HospitalUnknown
-
Dr. Sabrina OverhagenActive, not recruitingThoracoabdominal Aortic Aneurysm, Without Mention of Rupture | Abdominal Aortic Aneurysm, Without Mention of RuptureGermany
-
EndologixCompleted